On May 1, 2026, the U.S. Food and Drug Administration approved vepdegestrant — marketed as VEPPANU and developed by Arvinas — for the treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer harbouring ESR1 mutations in patients who have progressed on prior endocrine-based therapy. The approval makes vepdegestrant the first proteolysis-targeting chimera, or PROTAC, to receive regulatory clearance in any oncology indication, and only the third oral selective estrogen receptor degrader (SERD) to reach patients.
The distinction matters. Unlike conventional SERDs that block estrogen from binding its receptor, vepdegestrant recruits an intracellular E3 ubiquitin ligase to physically tag the estrogen receptor protein for degradation by the cell’s own proteasome machinery. The result is near-complete elimination of the receptor rather than simple occupancy blockade. In tumours where ESR1 mutations have altered the ligand-binding domain to confer constitutive receptor activity — a resistance mechanism seen frequently after aromatase inhibitor treatment — this degradation approach theoretically overcomes the structural changes that blunt conventional antagonists.
The approval was supported by data from VERITAC-2, a randomised, open-label Phase 3 trial that compared vepdegestrant head-to-head against fulvestrant, the incumbent injectable SERD. In the ESR1-mutated population, vepdegestrant extended progression-free survival by approximately three months relative to fulvestrant and demonstrated a favourable safety profile consistent with the broader SERD class. The FDA also approved the Guardant360 CDx liquid biopsy assay as a companion diagnostic to identify ESR1-mutation-positive patients eligible for treatment.
ESR1 mutations are detected in roughly 25 to 40 percent of patients with metastatic ER-positive breast cancer after aromatase inhibitor exposure, making this a sizeable and underserved patient population. Current standard care typically sequences patients through CDK4/6 inhibitor combinations before reaching the ESR1-mutated salvage setting, but options at that point have remained limited.
Beyond the immediate clinical utility, the approval validates the PROTAC platform more broadly. Several other targeted protein degraders are in clinical development for castration-resistant prostate cancer, haematologic malignancies, and solid tumours driven by historically undruggable transcription factors. Arvinas itself has ARV-766, a second-generation androgen receptor degrader, advancing through late-phase studies.
Vepdegestrant joins elacestrant (Orserdu) and camizestrant in the oral SERD class, though its mechanism of action as a bifunctional degrader differentiates it from the pure receptor antagonists in that cohort. Oncologists will now weigh whether the added degradation mechanism translates to durable benefit in a tumour biology shaped by rapid adaptive resistance.
The approval marks a maturation point for a drug design strategy that began as an academic concept in the early 2000s and spent nearly two decades in preclinical optimisation. That a PROTAC has now navigated a pivotal Phase 3 trial and won regulatory approval in a crowded oncology setting will accelerate investment in the broader targeted degradation space.
